Supplement

Impact of Proactive Integrated Care on Chronic Obstructive Pulmonary Disease

Patricia B. Koff, RRT, MEd^{1*}, Sung-joon Min, PhD^{2*}, Debora L. P. Diaz¹, Tammie J. Freitag, RN, BSN¹, Shannon S. James, RN, BSN¹, Norbert F. Voelkel, MD¹, Derek J. Linderman, MD¹, Fernando Diaz del Valle, MD¹, Richard K. Albert MD¹, Todd M. Bull MD¹, Arne Beck, PhD³, Thomas J. Stelzner, MD³, Debra P. Ritzwoller, PhD³, Christine M. Kveton, RRT³, Stephanie Carwin, RRT³, Moumita Ghosh, PhD⁴, Robert L. Keith, MD^{1, 5}; John M. Westfall, MD⁶ and R. William Vandivier, MD¹.

¹Division of Pulmonary Sciences and Critical Care Medicine, Colorado Pulmonary Outcomes Research Group (CPOR) and ²Division of Health Care Policy and Research, Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO; ³Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado; ⁴National Jewish Health, Denver, CO, ⁵Denver Veterans Administration Medical Center, Denver, Colorado; ⁶Department of Family Medicine, High Plains Research Network, University of Colorado Denver, Anschutz Medical Campus.

TABLES
Supplementary Table 1. Completers *Versus* Non-Completers*

| Characteristics | Non-Completers N = 122 | Completers N = 389 |
|--|---------------------------|-----------------------|
| Age, yr | 68.0 (9.8) | 68.4 (8.6) |
| Gender, % female | 41.0 | 38.8 |
| Race & Ethnicity | | |
| Caucasian, % | 87.7 | 92.8 |
| Non-Caucasian, % | 12.3 | 7.2 |
| BMI | 26.4 (5.4) | 26.4 (6.0) |
| FEV ₁ , % predicted | 36.9 (13.7) | 36.7 (13.4) |
| mMRC dyspnea score | 2.0 (1.0) | 1.9 (1.0) |
| Six minute walk distance, m | 255.7 (117.5) | 274.9 (116.2) |
| BODE index | 4.9 (2.1) | 4.7 (2.0) |
| Current smoker, % | 32.0 | 17.7 |
| Smoking history, pack-yr | 56.8 (31.4) | 58.9 (33.3) |
| Current or prior pulmonary rehabilitation, % | 21.3 | 35.7 |
| Lives alone, % | 27.0 | 30.1 |
| Education, yr | 13.0 (2.5) | 13.5 (2.5) |
| Influenza vaccination, % | 89.3 | 94.3 |
| Pneumococcal vaccination, % | 76.2 | 83.8 |
| Long-term O ₂ therapy, % | 82.0 | 81.5 |
| Resting O ₂ , L | 1.8 (1.5) | 1.8 (1.6) |

^{*}Authors contributed equally to the study.

| Post-exercise O ₂ , L | 2.5 (2.1) | 2.7 (2.0) |
|--|-------------|-------------|
| Sleep O ₂ , L | 2.1 (1.3) | 2.1 (1.5) |
| Resting SpO ₂ , % | 93.3 (2.9) | 92.7 (2.9) |
| Post-exercise SpO ₂ , % | 87.6 (5.4) | 87.8 (4.9) |
| Medications | 01.0 (0.1) | 07.0 (1.0) |
| SABA, % | 90.2 | 92.3 |
| LABA, % | 54.1 | 56.0 |
| SAMA, % | 54.1 | 40.1 |
| LAMA, % | 39.3 | 46.5 |
| ICS, % | 63.1 | 72.2 |
| Theophylline, % | 4.1 | 9.0 |
| Co-morbidities | | |
| Hypertension, % | 54.9 | 56.3 |
| Congestive heart failure, % | 27.9 | 15.4 |
| Diabetes, % | 16.4 | 15.2 |
| Obstructive sleep apnea, % | 16.4 | 16.5 |
| Prior year healthcare utilization (COPD) | | |
| ED visits, visits/patient | 1.07 (1.91) | 0.58 (1.20) |
| Hospitalizations, visits/patient | 0.79 (1.53) | 0.42 (1.07) |
| ICU hospitalizations, visits/patient | 0.19 (0.54) | 0.10 (0.41) |
| ICU hospitalizations with ventilation, | , | , |
| visits/patient | 0.15 (0.57) | 0.07 (0.32) |
| Hospital LOS, days | 3.70 (7.75) | 1.97 (5.36) |
| Urgent office visits, visits/patient | 1.17 (2.45) | 0.99 (1.99) |
| Prior year healthcare utilization (non- | , | , |
| COPD) | | |
| ED visits, visits/patient | 0.18 (0.56) | 0.21 (0.52) |
| Hospitalizations, visits/patient | 0.15 (0.49) | 0.13 (0.40) |
| Hospital LOS, days | 0.64 (2.71) | 0.61 (2.71) |
| Urgent office visits, visits/patient | 0.39 (1.31) | 0.25 (0.65) |
| SGRQ Scores | , , | , , |
| Total | 49.3 (16.8) | 47.7 (16.4) |
| Symptom | 57.2 (21.2) | 56.0 (21.0) |
| Activity | 67.4 (20.4) | 67.6 (19.7) |
| Impact | 36.5 (19.0) | 33.7 (17.2) |

^{*}The only significant differences in baseline characteristics between the two groups were the proportion of patients who were current smokers (p = 0.0008), had been treated with pulmonary rehabilitation (p = 0.003), used short-acting muscarinic antagonists (p = 0.007), had congestive heart failure (p = 0.002), and measures of education (p = 0.04), resting SpO₂, % (p = 0.049), and prior year COPD-related emergency department visits (p = 0.003), hospitalizations (p = 0.002), ICU hospitalizations (p = 0.03) and hospital length of stay (p = 0.002). Data are presented as mean (SD) unless otherwise stated.

Supplementary Table 2. Baseline Characteristics for Completers*

| Characteristics | Usual Care N = 140 | Proactive iCare N = 249 |
|--|-----------------------|----------------------------|
| • | | |
| Age, yr | 68.8 (9.0) | 68.2 (8.5) |
| Gender, % female | 32.9 | 42.2 |
| Race & Ethnicity | | |
| Caucasian, % | 93.6 | 92.4 |
| Non-Caucasian, % | 6.4 | 7.6 |
| BMI, units | 26.1 (5.4) | 26.6 (6.3) |
| FEV ₁ , % predicted | 37.5 (14.2) | 36.3 (13.0) |
| mMRC dyspnea score, units | 1.9 (1.0) | 1.9 (1.0) |
| Six minute walk distance, m | 276.8 (128.3) | 273.8 (109.1) |
| BODE index, units | 4.6 (2.1) | 4.8 (2.0) |
| Current smoker, % | 16.4 | 18.5 |
| Smoking history, pack-yr | 56.4 (34.6) | 58.6 (32.6) |
| Current or prior pulmonary rehabilitation, % | 31.4 | 38.2 |
| Lives alone, % | 28.6 | 30.9 |
| Education, yr | 13.5 (2.6) | 13.5 (2.5) |
| Influenza vaccination, % | 94.3 | 94.4 |
| Pneumococcal vaccination, % | 87.1 | 81.9 |
| Long-term O ₂ therapy, % | 76.4 | 84.3 |
| Resting O ₂ , L | 1.8 (1.7) | 1.8 (1.6) |
| Post-exercise O ₂ , L | 2.5 (2.0) | 2.8 (2.0) |
| Sleep O ₂ , L | 2.0 (1.5) | 2.2 (1.5) |
| Resting SpO ₂ , % | 92.6 (2.4) | 92.8 (3.2) |
| Post-exercise SpO ₂ , % | 87.9 (4.7) | 87.7 (5.1) |
| Medications | | |
| SABA, % | 90.7 | 93.2 |
| LABA, % | 50.0 | 59.4 |
| SAMA, % | 49.3 | 34.9 |
| LAMA, % | 38.6 | 51.0 |
| ICS, % | 63.6 | 77.1 |
| Theophylline, % | 9.3 | 8.8 |
| Co-morbidities | | |
| Hypertension, % | 55.7 | 56.6 |
| Congestive heart failure, % | 18.6 | 13.7 |
| Diabetes, % | 14.3 | 15.7 |
| Obstructive sleep apnea, % | 12.9 | 18.5 |
| Prior year healthcare utilization (COPD) | | |
| ED visits, visits/patient | 0.47 (1.19) | 0.63 (1.20) |
| Hospitalizations, visits/patient | 0.34 (0.79) | 0.47 (1.19) |
| ICU hospitalizations, visits/patient | 0.08 (0.42) | 0.12 (0.41) |
| ICU hospitalizations with ventilation, | 0.07 (0.39) | 0.07 (0.27) |
| visits/patient | | . , |
| Hospital LOS, days | 1.64 (4.57) | 2.17 (5.76) |
| | | |
| Urgent office visits, visits/patient | 0.67 (1.15) | 1.16 (2.32) |

| COPD) | | |
|--------------------------------------|-------------|-------------|
| ED visits, visits/patient | 0.23 (0.57) | 0.20 (0.49) |
| Hospitalizations, visits/patient | 0.13 (0.38) | 0.12 (0.41) |
| Hospital LOS, days | 0.46 (1.76) | 0.69 (3.12) |
| Urgent office visits, visits/patient | 0.26 (0.68) | 0.25 (0.63) |
| SGRQ Scores | , , | , , |
| Total | 45.4 (18.2) | 48.9 (15.2) |
| Symptom | 53.7 (22.7) | 57.3 (20.0) |
| Activity | 65.4 (21.2) | 68.8 (18.7) |
| Impact | 31.5 (18.9) | 35.0 (16.1) |

^{*}The only significant differences in baseline characteristics between the two trial groups were the proportion of patients using short-acting muscarinic antagonists (p = 0.006), long-acting muscarinic antagonists (p = 0.02) or inhaled corticosteroids (p = 0.004), and prior year COPD-related emergency department visits (p = 0.03) and urgent office visits (p = 0.03). Data are presented as mean (SD) unless otherwise stated.

Supplementary Table 3. Comparison of Urban and Rural Baseline Differences*

| Characteristics | Urban N = 403 | Rural N = 108 |
|---|----------------------------|------------------|
| Age, yr | 68.3 (9.0) | 68.4 (8.8) |
| Gender, % female | 39.2 | 39.8 |
| Race & Ethnicity | 00.2 | 00.0 |
| Caucasian, % | 90.8 | 94.4 |
| Non-Caucasian, % | 9.2 | 5.6 |
| BMI, units | 26.5 (5.9) | 26.3 (5.8) |
| FEV ₁ , % predicted | 36.7 (13.1) | 37.1 (14.8) |
| mMRC dyspnea score, units | 1.9 (0.9) | 1.9 (1.1) |
| Six minute walk distance, m | 272.9 (115 [.] 0) | 261.0 (123.1) |
| BODE index, units | 4.7 (2.0) | 4.8 (2.3) |
| Current smoker, % | 19.6 ´ | 26.9 ´ |
| Smoking history, pack-yr | 58.1 (32.6) | 59.5 (33.9) |
| Current or prior pulmonary rehabilitation, % | 35.7 ´ | 19̀.4 |
| Lives alone, % | 26.8 | 38.9 |
| Education, yr | 13.6 (2.3) | 12.5 (3.0) |
| Influenza vaccination, % | 94.3 | 88.9 |
| Pneumococcal vaccination, % | 81.9 | 82.4 |
| Long-term O ₂ therapy, % | 82.4 | 78.7 |
| Resting O ₂ , L | 1.8 (1.6) | 1.7 (1.5) |
| Post-exercise O ₂ , L | 2.7 (2.0) | 2.3 (1.9) |
| Sleep O ₂ , L | 2.2 (1.4) | 2.0 (1.5) |
| Resting SpO ₂ , % | 93.0 (2.6) | 92.5 (3.8) |
| Post-exercise SpO ₂ , % | 87.8 (4.9) | 87.5 (5.5) |
| Medications | | |
| SABA, % | 93.5 | 85.2 |
| LABA, % | 56.1 | 53.7 |
| SAMA, % | 46.9 | 30.6 |
| LAMA, % | 44.4 | 46.3 |
| ICS, % | 71.7 | 63.9 |
| Theophylline, % | 7.9 | 7.4 |
| Co-morbidities | | |
| Hypertension, % | 56.3 | 54.6 |
| Congestive heart failure, % | 17.1 | 23.1 |
| Diabetes, % | 16.1 | 13.0 |
| Obstructive sleep apnea, % | 15.1 | 21.3 |
| Prior year healthcare utilization (COPD) | 0.00 (4.05) | 2 22 (1 2 1) |
| ED visits, visits/patient | 0.69 (1.35) | 0.69 (1.64) |
| Hospitalizations, visits/patient | 0.49 (1.00) | 0.59 (1.77) |
| ICU hospitalizations, visits/patient | 0.14 (0.49) | 0.05 (0.21) |
| ICU hospitalizations with ventilation, visits/patient | 0.10 (0.43) | 0.04 (0.19) |
| Hospital LOS, days | 2.33 (5.74) | 2.60 (7.12) |
| Urgent office visits, visits/patient | 1.04 (1.99) | 0.98 (2.50) |
| Prior year healthcare utilization (non- | 1.01 (1.00) | 0.00 (2.00) |

| COPD) | | |
|--------------------------------------|-------------|-------------|
| ED visits, visits/patient | 0.18 (0.47) | 0.28 (0.69) |
| Hospitalizations, visits/patient | 0.12 (0.36) | 0.17 (0.59) |
| Hospital LOS, days | 0.50 (2.20) | 1.04 (4.06) |
| Urgent office visits, visits/patient | 0.32 (0.92) | 0.16 (0.53) |
| SGRQ Scores | , , | , , |
| Total | 48.1 (16.4) | 47.8 (16.9) |
| Symptom | 55.6 (21.4) | 59.0 (19.7) |
| Activity | 68.2 (19.5) | 65.1 (21.0) |
| Impact | 34.3 (17.7) | 34.6 (17.8) |

^{*}The only significant differences in baseline characteristics between the two groups were the proportion of patients who had been treated with pulmonary rehabilitation (p = 0.001), living alone (p = 0.01), influenza vaccination (p = 0.048), use of short-acting beta-agonists (p = 0.005) or short-acting muscarinic antagonists (p = 0.002), measures of education (p = 0.0003), post-exercise O_2 (0.04), and prior year non-COPD-related urgent office visits (p = 0.03). Data are presented as mean (SD) unless otherwise stated.

Supplementary Table 4. Urban Baseline Characteristics*

| Age, yr 68.1 (9.5) 68.4 (8.7) Gender, % female 32.3 42.5 Race & Ethnicity 32.3 42.5 Caucasian, % 92.3 90.1 Non-Caucasian, % 7.7 9.9 BMI, units 26.0 (5.4) 26.7 (6.1) FEV-1, % predicted 36.7 (14.3) 36.7 (12.6) MMRC dyspnea score, units 1.9 (0.9) 2.0 (0.9) Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units 4.7 (2.1) 4.8 (1.9) Current smoker, % 22.3 18.3 Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Resting O ₂ , L 1.9 (1.8) 1.8 (1.5) Post-exercise O ₂ , L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ , L 2.2 (1.5) 2.2 (1.4) | Characteristics | Usual Care N = 130 | Proactive iCare N = 273 |
|---|---|-----------------------|----------------------------|
| Gender, % female 32.3 42.5 Race & Ethnicity 20.3 90.1 Caucasian, % 92.3 90.1 Non-Caucasian, % 7.7 9.9 BMI, units 26.0 (5.4) 36.7 (12.6) FEV1, % predicted 36.7 (14.3) 36.7 (12.6) mMRC dyspnea score, units 1.9 (0.9) 2.0 (0.9) Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units 4.7 (2.1) 4.8 (1.9) Current smoker, % 22.3 18.3 Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O ₂ therapy, % 76.9 85.0 Resting O ₂ L 1.9 (1.8) 1.8 (1.5) Post-exercise O ₂ , L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ , L 2.7 (2.2) 2.8 (2.0) | | 14 - 130 | N - 273 |
| Race & Ethnicity 92.3 90.1 Non-Caucasian, % 7.7 9.9 BMI, units 26.0 (5.4) 26.7 (6.1) FEV1, % predicted 36.7 (14.3) 36.7 (12.6) mMRC dyspnea score, units 1.9 (0.9) 2.0 (0.9) Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units 4.7 (2.1) 4.8 (1.9) Current smoker, % 22.3 18.3 Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 35.4 35.9 Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O ₂ therapy, % 76.9 85.0 Resting O ₂ , L 2.2 (1.5) 2.2 (1.4) Resting SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 80.0 (4.5) 87. | Age, yr | 68.1 (9.5) | 68.4 (8.7) |
| Caucasian, % 92.3 90.1 Non-Caucasian, % 7.7 9.9 BMI, units 26.0 (5.4) 26.7 (6.1) FEV1, % predicted 36.7 (14.3) 36.7 (12.6) mMRC dyspnea score, units 1.9 (0.9) 2.0 (0.9) Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units 4.7 (2.1) 4.8 (1.9) Current smoker, % 22.3 18.3 Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 35.4 35.9 Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O ₂ therapy, % 76.9 85.0 Resting O ₂ . L 1.9 (1.8) 1.8 (1.5) Post-exercise O ₂ . L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ . L 2.2 (1.5) 2.2 (1.4) Resting SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 60.9 56.0 Congestive heart failure, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 11.0 1.0 7.0 Postructive sleep apnea, % 16.2 16.1 Obstructive sleep apnea, % 16.2 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations, visits/patient 0.19 (0.90 (0.41) 0.11 (0.44) visits/patient 1.50 (0.73 (1.27) 1.19 (2.24) | Gender, % female | 32.3 | 42.5 |
| Non-Caucasian, % 7.7 9.9 | _ | | |
| BMI, units FEV1, % predicted MRC dyspnea score, units 1.9 (0.9) 2.0 (0.9) Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units Current smoker, % 22.3 3 18.3 Smoking history, pack-yr Current or prior pulmonary rehabilitation, % Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) Influenza vaccination, % 1.9 (0.9) 2.0 Long-term O ₂ therapy, % 76.9 Resting O ₂ , L 1.9 (1.8) Resting SpO ₂ , % Post-exercise SpO ₂ , % Resting | • | | |
| FEV1, % predicted | • | | |
| mMRC dyspnea score, units Six minute walk distance, m Six winute walk walk walk walk walk walk walk walk | • | • • | ` , |
| Six minute walk distance, m 274.2 (133.2) 272.2 (105.5) BODE index, units 4.7 (2.1) 4.8 (1.9) Current smoker, % 22.3 18.3 Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 35.4 35.9 Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O ₂ therapy, % 76.9 85.0 Resting O ₂ , L 1.9 (1.8) 1.8 (1.5) Post-exercise O ₂ , L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ , L 2.2 (1.5) 2.2 (1.4) Resting SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications 88.0 (4.5) 87.8 (5.1) SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 15.5 58.2 SAMA, % <td>•</td> <td>` ,</td> <td>,</td> | • | ` , | , |
| BODE index, units Current smoker, % 22.3 18.3 Smoking history, pack-yr Current or prior pulmonary rehabilitation, % Lives alone, % Education, yr Influenza vaccination, % Pneumococcal vaccination, % Resting O ₂ , L Resting O ₂ , L Resting SPO ₂ , % Resting SPO ₂ , % Restrices SpO ₂ , % | | ` , | ` , |
| Current smoker, % Smoking history, pack-yr Current or prior pulmonary rehabilitation, % Lives alone, % Education, yr 13.6 (2.3) Influenza vaccination, % Pneumococcal vaccination, % Long-term O ₂ therapy, % Resting O ₂ , L Resting SpO ₂ , L Resting SpO ₂ , % Post-exercise SpO ₂ , % Resting SpO ₂ , % SABA, % LABA, % SOBA, % SOB | | ` , | |
| Smoking history, pack-yr 56.3 (31.9) 59.0 (33.0) Current or prior pulmonary rehabilitation, % 35.4 35.9 Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O ₂ therapy, % 76.9 85.0 Resting O ₂ , L 1.9 (1.8) 1.8 (1.5) Post-exercise O ₂ , L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ , L 2.2 (1.5) 2.2 (1.4) Resting SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications 88.0 (4.5) 87.8 (5.1) Medications 82.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications 89.2 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications 80.2 42.5 SABA, % 92.3 94.1 </td <td></td> <td></td> <td>, ,</td> | | | , , |
| Current or prior pulmonary rehabilitation, % 35.4 35.9 Lives alone, % 24.6 27.8 Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O2 therapy, % 76.9 85.0 Resting O2, L 1.9 (1.8) 1.8 (1.5) Post-exercise O2, L 2.7 (2.2) 2.8 (2.0) Sleep O2, L 2.2 (1.5) 2.2 (1.4) Resting SpO2, % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications 92.3 94.1 LABA, % 51.5 58.2 SABA, % 51.5 58.2 SAMA, % 16.2 48.4 | · | | |
| Lives alone, % Education, yr Influenza vaccination, % Pneumococcal vaccination, % Resting O ₂ , L Long-term O ₂ therapy, % Resting O ₂ , L I.9 (1.8) Post-exercise O ₂ , L I.9 (1.8) Resting SpO ₂ , W Post-exercise O ₂ , L Resting SpO ₂ , % Post-exercise SpO ₂ , % Post-exercise SpO ₂ , % Post-exercise SpO ₂ , % Resting SpO ₂ , % Post-exercise SpO ₂ , % Resting SpO ₂ , b Resting SpO ₂ , w Resting SpO ₂ , w Resting SpO ₂ , % Resting SpO ₂ , w Resting O ₂ , L Resting SpO ₂ , w Resting O ₂ , L Resting O ₂ , R Resting O ₂ , L Resting O ₂ , L Resting O ₂ , L Resting O ₂ , R Resting O ₂ , L Resting O ₂ , R Resting O ₂ | | | |
| Education, yr 13.6 (2.3) 13.7 (2.3) Influenza vaccination, % 94.6 94.1 Pneumococcal vaccination, % 83.9 81.0 Long-term O2 therapy, % 76.9 85.0 Resting O2, L 1.9 (1.8) 1.8 (1.5) Post-exercise O2, L 2.7 (2.2) 2.8 (2.0) Sleep O2, L 2.2 (1.5) 2.2 (1.4) Resting SpO2, % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 1.55 58.2 SAMA, % 1.55 58.2 SAMA, % 1.00 7.0 7.0 Co-morbidites LOS, % 63.9 75.5 Theophylline, % 10.0 7.0 7.0 Co-morbidites Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) D.75 (1.27) D. | | | |
| Influenza vaccination, % Pneumococcal vaccination, % Resting O ₂ , L Resting O ₂ , L Sleep O ₂ , L Resting SpO ₂ , % Post-exercise SpO ₂ , % Resting O ₂ , % | • | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | • • | ` , | |
| Resting O2, L 1.9 (1.8) 1.8 (1.5) Post-exercise O2, L 2.7 (2.2) 2.8 (2.0) Sleep O2, L 2.2 (1.5) 2.2 (1.4) Resting SpO2, % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications 88.0 (4.5) 87.8 (5.1) SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.10 (0.41) 0.11 (0.44) Hospital LOS, days 1.87 (4.71) | Pneumococcal vaccination, % | 83.9 | 81.0 |
| Post-exercise O ₂ , L 2.7 (2.2) 2.8 (2.0) Sleep O ₂ , L 2.2 (1.5) 2.2 (1.4) Resting SpO ₂ , % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO ₂ , % 88.0 (4.5) 87.8 (5.1) Medications SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Value 10.0 7.0 Compestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations, visits/patient 0.18 (4.71) 2.55 (6.17) Urgent off | Long-term O₂ therapy, % | 76.9 | 85.0 |
| Sleep O2, L 2.2 (1.5) 2.2 (1.4) Resting SpO2, % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications 88.0 (4.5) 87.8 (5.1) SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.11 (0.45) 0.54 (1.06) ICU hospitalizations with ventilation, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.73 (1.27) 0.11 (0.44) Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urg | Resting O ₂ , L | 1.9 (1.8) | 1.8 (1.5) |
| Resting SpO2, % 92.7 (2.6) 93.2 (2.7) Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications \$8.0 (4.5) 87.8 (5.1) SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient 0.73 (1.27) 1.19 (2.24) | | ` , | , , |
| Post-exercise SpO2, % 88.0 (4.5) 87.8 (5.1) Medications SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient 0.73 (1.27) 1.19 (2.24) | · | | |
| Medications SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations with ventilation, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | ` , | , , |
| SABA, % 92.3 94.1 LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations with ventilation, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | • | 88.0 (4.5) | 87.8 (5.1) |
| LABA, % 51.5 58.2 SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations with ventilation, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | 00.0 | 04.4 |
| SAMA, % 56.2 42.5 LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 16.2 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient 1.87 (4.71) 2.55 (6.17) Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | | |
| LAMA, % 36.2 48.4 ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | | |
| ICS, % 63.9 75.5 Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) visits/patient 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | | |
| Theophylline, % 10.0 7.0 Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Visits/patient 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | • | | |
| Co-morbidities Hypertension, % 56.9 56.0 Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Visits/patient 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | • | | |
| Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | · | | |
| Congestive heart failure, % 21.5 15.0 Diabetes, % 16.2 16.1 Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | Hypertension, % | 56.9 | 56.0 |
| Obstructive sleep apnea, % 13.1 16.1 Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | 21.5 | 15.0 |
| Prior year healthcare utilization (COPD) ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Visits/patient 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | Diabetes, % | 16.2 | 16.1 |
| ED visits, visits/patient 0.55 (1.25) 0.76 (1.40) Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | | 13.1 | 16.1 |
| Hospitalizations, visits/patient 0.39 (0.85) 0.54 (1.06) ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, visits/patient 0.09 (0.41) 0.11 (0.44) Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | • | | |
| ICU hospitalizations, visits/patient 0.11 (0.45) 0.16 (0.50) ICU hospitalizations with ventilation, 0.09 (0.41) 0.11 (0.44) visits/patient Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | · | ` , | · · · |
| ICU hospitalizations with ventilation, visits/patient Hospital LOS, days Urgent office visits, visits/patient 0.09 (0.41) 0.11 (0.44) 0.15 (6.17) 0.73 (1.27) 1.19 (2.24) | · | ` , | ` , |
| visits/patient Hospital LOS, days Urgent office visits, visits/patient 1.87 (4.71) 2.55 (6.17) 0.73 (1.27) 1.19 (2.24) | · · · · · · · · · · · · · · · · · · · | ` , | ` , |
| Hospital LOS, days 1.87 (4.71) 2.55 (6.17) Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | • | 0.09 (0.41) | 0.11 (0.44) |
| Urgent office visits, visits/patient 0.73 (1.27) 1.19 (2.24) | · | 1 97 (4 71) | 2 55 (6 17) |
| | | • • • | , , , |
| | Prior year healthcare utilization (non- | 0.70 (1.27) | 1.10 (2.27) |

| COPD) | | |
|--------------------------------------|-------------|-------------|
| ED visits, visits/patient | 0.22 (0.56) | 0.17 (0.43) |
| Hospitalizations, visits/patient | 0.12 (0.35) | 0.12 (0.37) |
| Hospital LOS, days | 0.34 (1.25) | 0.53 (2.53) |
| Urgent office visits, visits/patient | 0.25 (0.69) | 0.35 (1.02) |
| SGRQ Scores | , | , |
| Total | 45.6 (18.1) | 49.3 (15.5) |
| Symptom | 53.6 (22.7) | 56.6 (20.7) |
| Activity | 65.7 (21.1) | 69.3 (18.6) |
| Impact | 31.7 (19.2) | 35.6 (16.9) |

^{*}The only significant differences in baseline characteristics between the two trial groups were the proportion of patients using long-term oxygen therapy (p = 0.047), short-acting muscarinic antagonists (p = 0.01), long-acting muscarinic antagonists (p = 0.02) or inhaled corticosteroids (p = 0.02), and measures of prior year COPD-related urgent office visits (p = 0.04) and the SGRQ impact score (p = 0.04). Data are presented as mean (SD) unless otherwise stated.

| Supplementary Table 5. Baseline Characterist | ics for Urban Comp | leters* |
|--|--------------------|-----------------|
| Characteristics | Usual Care | Proactive iCare |
| | N = 115 | N = 191 |
| | | |
| Age, yr | 68.8 (9.0) | 68.4 (8.5) |
| Gender, % female | 31.3 | 41.9 |
| Race & Ethnicity | | |
| Caucasian, % | 94.8 | 91.1 |
| Non-Caucasian, % | 5.2 | 8.9 |
| BMI, units | 26.1 (5.5) | 26.5 (6.2) |
| FEV ₁ , % predicted | 36.0 (13.7) | 36.4 (12.5) |
| mMRC dyspnea score, units | 1.9 (0.9) | 2.0 (0.9) |
| Six minute walk distance, m | 277.9 (130.6) | 275.9 (106.1) |
| BODE index, units | 4.7 (2.0) | 4.8 (1.9) |
| Current smoker, % | 18.3 | 14.7 |
| Smoking history, pack-yr | 56.8 (33.3) | 59.8 (32.3) |
| Current or prior pulmonary rehabilitation, % | 37.4 | 41.4 |
| Lives alone, % | 26.1 | 27.2 |
| Education, yr | 13.6 (2.4) | 13.8 (2.3) |
| Influenza vaccination, % | 94.8 | 94.2 |
| Pneumococcal vaccination, % | 87.0 | 82.2 |
| Long-term O ₂ therapy, % | 76.5 | 85.9 |
| Resting O ₂ , L | 1.8 (1.8) | 1.8 (1.5) |
| Post-exercise O ₂ , L | 2.6 (2.1) | 2.9 (2.0) |
| Sleep O ₂ , L | 2.1 (1.5) | 2.2 (1.4) |
| Resting SpO ₂ , % | 92.6 (2.5) | 93.0 (2.7) |
| Post-exercise SpO ₂ , % | 87.8 (4.4) | 87.8 (5.1) |
| Medications | | |
| SABA, % | 91.3 | 95.8 |
| LABA, % | 50.4 | 59.7 |
| SAMA, % | 53.9 | 37.7 |
| LAMA, % | 36.5 | 51.8 |
| ICS, % | 64.3 | 79.6 |
| Theophylline, % | 10.4 | 8.4 |
| Co-morbidities | | |
| Hypertension, % | 54.8 | 56.0 |
| Congestive heart failure, % | 18.3 | 10.5 |
| Diabetes, % | 14.8 | 16.2 |
| Obstructive sleep apnea, % | 12.2 | 16.8 |
| Prior year healthcare utilization (COPD) | | |
| ED visits, visits/patient | 0.50 (1.28) | 0.764(1.09) |
| Hospitalizations, visits/patient | 0.34 (0.82) | 0.45 (0.94) |
| ICU hospitalizations, visits/patient | 0.09 (0.45) | 0.14 (0.45) |
| ICU hospitalizations with ventilation, | 0.08 (0.42) | 0.08 (0.30) |
| visits/patient | | |
| Hospital LOS, days | 1.63 (4.60) | 2.04 (4.69) |
| Urgent office visits, visits/patient | 0.70 (1.15) | 1.14 (2.06) |
| Prior year healthcare utilization (non-COPD) | | |

| ED visits, visits/patient | 0.23 (0.56) | 0.19 (0.46) |
|--------------------------------------|-------------|-------------|
| Hospitalizations, visits/patient | 0.13 (0.36) | 0.13 (0.40) |
| Hospital LOS, days | 0.38 (1.32) | 0.69 (2.89) |
| Urgent office visits, visits/patient | 0.28 (0.72) | 0.29 (0.66) |
| SGRQ Scores | | |
| Total | 45.2 (18.3) | 49.3 (15.0) |
| Symptom | 53.4 (22.6) | 56.5 (20.2) |
| Activity | 65.4 (21.7) | 69.8 (17.9) |
| Impact | 31.2 (19.1) | 35.3 (16.1) |

^{*}The only significant differences in baseline characteristics between the two trial groups were the proportion of patients using long-term oxygen therapy (p = 0.04), short-acting muscarinic antagonists (p = 0.006), long-acting muscarinic antagonists (p = 0.009) or inhaled corticosteroids (p = 0.003), and measures of prior year COPD-related emergency department visits (p = 0.03), urgent office visits (p = 0.049) and the total SGRQ score (p = 0.047). Data are presented as mean (SD) unless otherwise stated.

Supplementary Table 6. Urban Quality of Life Measured by the St. George's Respiratory Questionnaire

| Usual Care | | | I Care Gro | oup | Proact | ive iCare (| Group | Between Group | Between Group Difference | |
|--------------------|-----|------------------------------|-------------------------|-------------------------|--------|------------------------------|------------------------------|---------------------------|---------------------------|---------|
| Variable | N | Baseline Score | Time- point Score | Change from Baseline | N | Baseline Score | Time- point Score | Change from Baseline | Difference | p-value |
| Total Score | | | | | | | | | | |
| 3-mth | 120 | 45.9 (17.9) | 48.3 (17.1) | 2.34 (0.05, 4.63) | 224 | 48.9 (15.1) | 42.9 (15.1) | -5.96 (-7.35, -4.56) | -8.29 (-10.97, -5.62) | <0.0001 |
| 6-mth | 110 | `45.5 [´] (17.9) | 47.6 (18.9) | 2.14 (-0.49, 4.78) | 196 | `49.4 [´] (14.9) | `41.4 [´] (15.0) | -8.05 (-9.63, -6.48) | -10.20 (-13.26, -7.14) | <0.0001 |
| 9-mth | 115 | 45.2 (18.3) | 47.4 (18.4) | 2.12 (-0.30, 4.55) | 191 | 49.3 (15.0) | 41.6 (14.8) | -7.69 (-9.26, -6.12) | -9.82 (-12.70, -6.94) | <0.0001 |
| Symptom | | | | | | | | | | |
| 3-mth | 120 | 53.6 (22.3) | 54.3 (21.7) | 0.68 (-2.60, 3.95) | 224 | 56.4 (20.4) | 47.5 (20.5) | -8.91 (-11.38, -6.43) | -9.58 (-13.71, -5.45) | <0.0001 |
| 6-mth | 110 | 53.7 (22.8) | 51.8 (22.3) | -1.83 (-5.71, 2.05) | 196 | 56.0 (20.6) | 45.3 (20.1) | -10.66 (-13.40, -7.93) | -8.83 | <0.001 |
| 9-mth | 115 | 53.4 (22.6) | 53.1 (21.8) | -0.36 (-4.19, 3.48) | 191 | 56.5 (20.2) | 46.9 (18.4) | -9.57 (-12.47, -6.68) | -9.22 | <0.001 |
| Activity | | | | | | | | | | |
| 3-mth | 120 | 66.3 (20.6) | 68.7 (19.2) | 2.41 (-0.48, 5.30) | 224 | 69.1 (18.0) | 64.6 (18.3) | -4.56 (-6.36, -2.76) | -6.97 (-10.20, -3.74) | <0.0001 |
| 6-mth | 110 | 65.4 (20.6) | 65.8 (21.5) | 0.40 (-2.76, 3.56) | 196 | 70.1 (17.8) | 62.8 (18.5) | -7.33 (-9.32, -5.34) | -7.73 (-11.45, -4.01) | <0.0001 |
| 9-mth | 115 | 65.4 (21.7) | 65.9 (20.1) | 0.49 (-2.35, 3.32) | 191 | 69.8 (17.9) | 62.2 (20.0) | -7.53 (-9.51, -5.56) | -8.02 (-11.37, -4.67) | <0.0001 |
| Impact | | | | | | | | | | |
| 3-mth | 120 | 31.9 (19.2) | 34.8 (18.3) | 2.84 (0.29, 5.38) | 224 | 35.1 (16.4) | 29.2 (15.9) | -5.83 (-7.34, -4.32) | -8.67 (-11.62, -5.72) | <0.0001 |
| 6-mth | 110 | 31.6 (19.2) | 36.0 (19.7) | 4.37 (1.43, 7.32) | 196 | 35.5 (16.1) | 28.0 (15.8) | -7.50 (-9.31, -5.68) | -11.87 (-15.31, -8.43) | <0.0001 |
| 9-mth | 115 | 31.2 (19.1) | 35.0 (20.4) | 3.81 (0.89, 6.74) | 191 | 35.3 (16.1) | 28.1 (15.3) | -7.27 (-9.03, -5.51) | -11.08 (-14.49, -7.68) | <0.0001 |

Baseline and time-point scores are presented as mean (SD), and changes and differences are presented as mean (95% CI). P-values shown for the comparison between Proactive iCare and Usual Care groups. T-tests were used.

Supplementary Table 7. Urban Smoking, Symptoms, Exercise Capacity and Guideline-based Care

| | Usual Care | | | | Proactive iCare | | | Inter-group Difference | |
|---------------------------------------|---------------|---------------|-------------------------|---------------|-----------------|-------------------------|-------------------------|---------------------------|--|
| Measurement/ Treatment | Baseline | 9 Months | Change from Baseline | Baseline | 9 Months | Change from Baseline | Difference | p- value | |
| FEV ₁ , % predicted | 36.0 (13.7) | 35.9 (14.3) | -0.38 (-2.12, 1.37) | 36.4 (12.5) | 32.9 (13.0) | -3.52 (-4.88, -2.16) | -3.14 (-5.37, -0.92) | 0.006 | |
| mMRC dyspnea scale | 1.9 (0.9) | 2.1 (1.0) | 0.22 (0.05, 0.39) | 2.0 (0.9) | 1.9 (0.9) | -0.03 (-0.15, 0.10) | -0.24 (-0.45, -0.04) | 0.02 | |
| 6MWD, m | 277.9 (130.6) | 284.5 (126.8) | 4.00 (-16.26, 24.18) | 275.9 (106.1) | 328.1 (132.4) | 50.27 (35.40, 65.14) | 46.31 (21.41, 71.22) | 0.0003 | |
| BODE index | 4.7 (2.0) | 4.8 (2.1) | 0.19 (-0.06, 0.45) | 4.8 (1.9) | 4.5 (2.0) | -0.26 (-0.48, -0.04) | -0.45 (-0.79, -0.11) | 0.009 | |
| Sputum, % | 44.3 | 51.3 | , | 46.6 | 40.8 | , | , | 0.03 | |
| Post-exercise SpO ₂ , % | 87.8 (4.4) | 87.9 (4.0) | -0.02 (-0.79, 0.75) | 87.8 (5.1) | 89.6 (3.3) | 1.53 (0.78, 2.30) | 1.56 (0.49, 2.63) | 0.005 | |

Baseline and 9-month data are presented as mean (SD), and changes and differences are presented as mean (95% CI) unless otherwise stated.

Definition of abbreviations: mMRC = modified medical research council, 6MWD = 6 minute walk distance, LAMA = long-acting muscarinic antagonist, SAMA = short-acting muscarinic antagonist, LABA = long-acting beta-agonist, ICS = inhaled corticosteroid.

P-values shown for the comparison between Proactive iCare and Usual Care groups. T-tests were used for continuous variables, and logistic regression and chi-square tests were used for dichotomous variables.

Supplementary Table 8. Urban Healthcare Utilization Pre-post Difference in 9-month Rate, per Patient

| Variable | Usual Care N=115 | Proactive iCare N=191 | Difference | p-value |
|-----------------------------|---------------------|--------------------------|----------------|---------|
| COPD Healthcare | 14-110 | 14-101 | | |
| Hospitalizations, | -0.08 | -0.16 | -0.08 | 0.51 |
| visits/patient | (-0.24, -0.08) | (-0.31, -0.02) | (-0.30, 0.14) | |
| ICU hospitalizations, | -0.01 | -0.11 | -0.11 | 0.053 |
| visits/patient | (-0.10, 0.09) | (-0.18, -0.05) | (-0.22, 0.00) | |
| ICU hospitalizations with | -0.02 | -0.08 | -0.06 | 0.17 |
| ventilation, visits/patient | (-0.10, 0.06) | (-0.12, -0.03) | (-0.15, 0.04) | |
| Hospital LOS, days | -0.38* | · -1.02 | -0.64 | 0.27 |
| , , | (-1.51, 0.75) | (-1.64, -0.40) | (-1.92, 0.64) | |
| ED visits, visits/patient | -0.18 | -0.30 | -0.12 | 0.12 |
| | (-0.38, 0.02) | (-0.47, -0.14) | (-0.39, 0.01) | |
| Urgent office visits, | 0.15 | -0.62 | -0.77 | <0.0001 |
| visits/patient | (-0.10, 0.40) | (-0.99, -0.32) | (-1.16, -0.39) | |
| Non-COPD Healthcare | , , | , | , | |
| Hospitalizations, | 0.03 | 0.05 | 0.02 | 0.75 |
| visits/patient | (-0.08, 0.15) | (-0.03, 0.13) | (-0.12, 0.15) | |
| Hospital LOS, days | 0.49 | -0.04 | -0.52 | 0.81 |
| | (-0.29, 1.26) | (-0.54, 0.47) | (-1.44, 0.40) | |
| ED visits, visits/patient | -0.02 | 0.16 | 0.17 | 0.29 |
| | (-0.13, 0.10) | (0.02, 0.29) | (-0.00, 0.35) | |
| Urgent office visits, | 0.15 | 0.15 | -0.01 | 0.74 |
| visits/patient | (-0.01, 0.31) | (-0.01, 0.30) | (-0.23, 0.21) | |

Data are presented as mean (95% CI).

Definition of abbreviations: ED = emergency department, ICU = intensive care unit, LOS = length of stay.

P-values shown for the comparison between Proactive iCare and Usual Care groups. Wilcoxon tests were used for continuous variables.

^{*}Excluding one patient with pre-post difference = 195 days

Supplementary Figure 1




FIGURE LEGENDS

Supplementary Figure 1. Urban Cohort Quality of Life. This figure shows how quality of life changed from baseline at 3, 6 and 9 months in the Usual Care (UC) and Proactive Integrated Care (PiC) groups of the urban cohort. Quality of life measured by the A) total, B) symptom, C) activity and D) impact domains of the St. George's Respiratory Questionnaire (SGRQ) are shown ± 95% CI. T-tests were used to compare differences in the change from baseline for the UC and PiC groups at each time-point.